Loading…
Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome
Objectives We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE). Methods In total, 224 patients with SLE were studied, of whom 105 were aPL-positi...
Saved in:
| Published in: | Lupus 2014-08, Vol.23 (9), p.913-918 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623 |
| container_end_page | 918 |
| container_issue | 9 |
| container_start_page | 913 |
| container_title | Lupus |
| container_volume | 23 |
| creator | Deák, M Bocskai, M Burcsár, S Dányi, O Fekete, Z Kovács, L |
| description | Objectives
We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).
Methods
In total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features.
Results
Not only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p |
| doi_str_mv | 10.1177/0961203314531839 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1709395995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203314531839</sage_id><sourcerecordid>3366907951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623</originalsourceid><addsrcrecordid>eNqFkc1LxDAQxYMoun7cPUnBi5dq0iRNchTxC0Qvei5pmrpZ26ZmUmT_e7OsiiyIh2GYmd97ITyEjgk-J0SIC6xKUmBKCeOUSKq20IwwIfK0L7bRbHXOV_c9tA-wwBhTospdtFcwUahCqBnSj37I4zz4vvY2VedMFhy8ZW7IYAnR9mnRTeMEmQ3LOLe9jh7SpAG8cTraJvtwcZ7pIbpx7iFV50bXJPXQJFt7iHZa3YE9-uoH6OXm-vnqLn94ur2_unzIDWM45ryueV0yjduWUGVULXVZE6mxlLoRxloheVkrY1pNMBeMFdqqsmGUcEV4WdADdLb2HYN_nyzEqndgbNfpwfoJKiKwooorxf9HS0kpU1LhhJ5uoAs_hSF9pCKcUSE4xTJReE2Z4AGCbasxuF6HZUVwtUqq2kwqSU6-jKe6t82P4DuaBORrAPSr_fXqX4afRRCbxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1543775308</pqid></control><display><type>article</type><title>Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Deák, M ; Bocskai, M ; Burcsár, S ; Dányi, O ; Fekete, Z ; Kovács, L</creator><creatorcontrib>Deák, M ; Bocskai, M ; Burcsár, S ; Dányi, O ; Fekete, Z ; Kovács, L</creatorcontrib><description>Objectives
We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).
Methods
In total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features.
Results
Not only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p < 0.05). The APS + SLE subgroup more frequently required intensive immunosuppressive treatment than did the APS-negative patients (p < 0.05).
Conclusions
SLE patients with aPL positivity or secondary APS also have a higher risk to develop non-thromboembolic disease manifestations in addition to the aPL-related symptoms, and are predisposed to more severe SLE manifestations.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203314531839</identifier><identifier>PMID: 24729279</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anemia ; Antibodies ; Anticoagulants ; Antiphospholipid Syndrome - complications ; Disease ; Endocarditis ; Female ; Humans ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic - complications ; Male ; Middle Aged ; Retrospective Studies ; Rheumatology ; Risk Factors ; Thrombocytopenia ; Thromboembolism ; Thromboembolism - etiology ; Young Adult</subject><ispartof>Lupus, 2014-08, Vol.23 (9), p.913-918</ispartof><rights>The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</rights><rights>The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.</rights><rights>SAGE Publications © Aug 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623</citedby><cites>FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24729279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deák, M</creatorcontrib><creatorcontrib>Bocskai, M</creatorcontrib><creatorcontrib>Burcsár, S</creatorcontrib><creatorcontrib>Dányi, O</creatorcontrib><creatorcontrib>Fekete, Z</creatorcontrib><creatorcontrib>Kovács, L</creatorcontrib><title>Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Objectives
We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).
Methods
In total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features.
Results
Not only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p < 0.05). The APS + SLE subgroup more frequently required intensive immunosuppressive treatment than did the APS-negative patients (p < 0.05).
Conclusions
SLE patients with aPL positivity or secondary APS also have a higher risk to develop non-thromboembolic disease manifestations in addition to the aPL-related symptoms, and are predisposed to more severe SLE manifestations.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia</subject><subject>Antibodies</subject><subject>Anticoagulants</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Disease</subject><subject>Endocarditis</subject><subject>Female</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><subject>Thrombocytopenia</subject><subject>Thromboembolism</subject><subject>Thromboembolism - etiology</subject><subject>Young Adult</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqFkc1LxDAQxYMoun7cPUnBi5dq0iRNchTxC0Qvei5pmrpZ26ZmUmT_e7OsiiyIh2GYmd97ITyEjgk-J0SIC6xKUmBKCeOUSKq20IwwIfK0L7bRbHXOV_c9tA-wwBhTospdtFcwUahCqBnSj37I4zz4vvY2VedMFhy8ZW7IYAnR9mnRTeMEmQ3LOLe9jh7SpAG8cTraJvtwcZ7pIbpx7iFV50bXJPXQJFt7iHZa3YE9-uoH6OXm-vnqLn94ur2_unzIDWM45ryueV0yjduWUGVULXVZE6mxlLoRxloheVkrY1pNMBeMFdqqsmGUcEV4WdADdLb2HYN_nyzEqndgbNfpwfoJKiKwooorxf9HS0kpU1LhhJ5uoAs_hSF9pCKcUSE4xTJReE2Z4AGCbasxuF6HZUVwtUqq2kwqSU6-jKe6t82P4DuaBORrAPSr_fXqX4afRRCbxw</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Deák, M</creator><creator>Bocskai, M</creator><creator>Burcsár, S</creator><creator>Dányi, O</creator><creator>Fekete, Z</creator><creator>Kovács, L</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome</title><author>Deák, M ; Bocskai, M ; Burcsár, S ; Dányi, O ; Fekete, Z ; Kovács, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia</topic><topic>Antibodies</topic><topic>Anticoagulants</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Disease</topic><topic>Endocarditis</topic><topic>Female</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><topic>Thrombocytopenia</topic><topic>Thromboembolism</topic><topic>Thromboembolism - etiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deák, M</creatorcontrib><creatorcontrib>Bocskai, M</creatorcontrib><creatorcontrib>Burcsár, S</creatorcontrib><creatorcontrib>Dányi, O</creatorcontrib><creatorcontrib>Fekete, Z</creatorcontrib><creatorcontrib>Kovács, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deák, M</au><au>Bocskai, M</au><au>Burcsár, S</au><au>Dányi, O</au><au>Fekete, Z</au><au>Kovács, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>23</volume><issue>9</issue><spage>913</spage><epage>918</epage><pages>913-918</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objectives
We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).
Methods
In total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features.
Results
Not only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p < 0.05). The APS + SLE subgroup more frequently required intensive immunosuppressive treatment than did the APS-negative patients (p < 0.05).
Conclusions
SLE patients with aPL positivity or secondary APS also have a higher risk to develop non-thromboembolic disease manifestations in addition to the aPL-related symptoms, and are predisposed to more severe SLE manifestations.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>24729279</pmid><doi>10.1177/0961203314531839</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2014-08, Vol.23 (9), p.913-918 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1709395995 |
| source | SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list) |
| subjects | Adult Aged Aged, 80 and over Anemia Antibodies Anticoagulants Antiphospholipid Syndrome - complications Disease Endocarditis Female Humans Laboratories Lupus Lupus Erythematosus, Systemic - complications Male Middle Aged Retrospective Studies Rheumatology Risk Factors Thrombocytopenia Thromboembolism Thromboembolism - etiology Young Adult |
| title | Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T12%3A08%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-thromboembolic%20risk%20in%20systemic%20lupus%20erythematosus%20associated%20with%20antiphospholipid%20syndrome&rft.jtitle=Lupus&rft.au=De%C3%A1k,%20M&rft.date=2014-08-01&rft.volume=23&rft.issue=9&rft.spage=913&rft.epage=918&rft.pages=913-918&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203314531839&rft_dat=%3Cproquest_cross%3E3366907951%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c440t-5bb5b64a0ff139c9b8a6b18a088ad7cee7856b9ccfa1057442ae96d4315915623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1543775308&rft_id=info:pmid/24729279&rft_sage_id=10.1177_0961203314531839&rfr_iscdi=true |